Integrin β1 activity controls colony morphology during human pluripotent stem cell state transitions
Stem Cell Reports. 2025 Jun 17:102538. doi: 10.1016/j.stemcr.2025.102538. Online ahead of print.
Published on June 20, 2025
ABSTRACT
Integrin β1-mediated adhesion is dispensable in early mouse embryogenesis (pre-implantation) but indispensable post-implantation, suggesting distinct roles for β1-integrin-mediated adhesions in the naive (pre-implantation) versus primed (post-implantation) pluripotent stem cells (PSCs). We investigated the role of integrin β1 in regulating naive-like and primed human induced PSC (hiPSC) states. We find that integrin β1 is active in both in vitro. In primed hiPSCs, integrin β1 inhibition induces naive-like colony features, reduces actomyosin contraction and extracellular signal-regulated kinase (ERK) activity, and alters gene expression, indicative of more naive-like features. These resemble the dramatic reorganization of the colony morphology, actin cytoskeleton, and adhesions upon chemical reversion from primed to naive states of pluripotency. Importantly, functional and single-cell transcriptomics analyses demonstrate that integrin β1 inhibition attenuates colony morphology transitions in cells exiting naive pluripotency. These data reveal unprecedented integrin-dependent regulation of PSC states and demonstrate how integrin inhibitors may help to fine-tune hiPSC function and properties in vitro.
PMID:40541174 | DOI:10.1016/j.stemcr.2025.102538
Latest Publications
- XMD8-92 and JWG-045 exhibit anti-ferroptotic activities, independently of inhibiting ERK5
- Molecular Characterization of Extracellular Vesicles From Human B Cell Lymphomas: Methodological Comparison to Vesicles From Patient Serum
- Evolving epigenomics of immune cells at single-nucleus resolution in children en route to type 1 diabetes
- Restoring the tumour mechanophenotype of vocal fold cancer reverts its malignant properties
- Spatial single-cell analysis reveals tumor microenvironment signatures predictive of oral cavity cancer outcome